Cardiovascular disease preventive effects of aspirin combined with different statins in the United States general population. The leading brand of RozoLip ASP being promoted by Edinburgh Pharmaceuticals in India.

-

 

Abstract

The purpose of this study was to explore the use of aspirin in conjunction with various statins for cardiovascular disease (CVD) prevention in the general population of the United States (U.S.). A total of 3778 people from the National Health and Nutrition Examination Surveys from 2011 to 2018 were included in our analysis. After adjusting for sociodemographic and common cardiovascular risk factors, we used multivariable logistic regression analysis to determine aspirin should be combined with which type of statin for better CVD preventive effects. Subgroup analyses were carried out subsequently. In comparison to the aspirin use alone, the odds ratios with 95% confidence intervals for CVD were 0.43 (0.33, 0.57), 0.69 (0.42, 1.13), 0.44 (0.31, 0.62), 0.34 (0.23, 0.50) and 0.64 (0.49, 0.84) for the combination use of aspirin and atorvastatin, lovastatin, pravastatin, rosuvastatin as well as simvastatin, respectively, in the fully-adjusted model. 




Aspirin combined with rosuvastatin was more effective in the prevention of individual CVD, including congestive heart failure, coronary heart disease, angina pectoris and heart attack, than aspirin combined with other statins. In conclusion, statins combined with aspirin have a clear advantage over aspirin alone in preventing CVD. In addition, when various sex, age, and fitness levels were considered, as well as with and without diabetes mellitus, the combination usage of aspirin and rosuvastatin had the greatest CVD preventive effects than aspirin coupled with other statins.

Courtesy  

Tao Liu 1, Ronghua Zuo 2, Jia Wang 3, Zixuan Huangtao 4, Bing Wang 1, Lifang Sun 1, Shasha Wang 1, Baoyin Li 1, Zhijian Zhu 1, Yesheng Pan 5
Affiliations 
  • PMID: 36941404
    •  
  • PMCID: PMC10027662
    •  
  • DOI: 10.1038/s41598-023-31739-w


Get More Information Click On This Website Link - www.edinburghpharma.in and QR Code


Click on Social Accounts - Facebook , LinkedIn & YouTube 






#Pharma Franchise in Odisha #Anti-Diabetic PCD# Best PCD Pharma Franchise Company# High Quality Pharma Product# Third Party manufacturing # Top 10 Pharma Franchise# PCD in Uttar Pradesh# Monopoly Phama PCD# Best Pharma Franchise # PCD in Assam# Phama Franchise in Andhra Pradesh, top Pcd Pharma Franchise in India, Medicine Franchise Company List, Pharmaceutical Manufacturing Companies Near Me, Pcd Pharma Franchise Company in Gujarat, Best Pharma Companies, Best Derma PCD Franchise 


Comments

Post a Comment

Popular posts from this blog

Fixed-Dose Combination of Dapagliflozin + Sitagliptin + Metformin in Patients with Type 2 Diabetes Poorly Controlled with Metformin: Phase 3, Randomized Comparison with Dual Combinations. Leading Brands Available in India for Dapagliflozin + Sitagliptin + Metformin is SITPIN DM Promoted by Edinburgh Pharmaceuticals.

-
Image
Abstract Introduction:  This study compared efficacy and safety of triple drug fixed-dose combination (FDC) of dapagliflozin (DAPA) + sitagliptin (SITA) + metformin (MET) extended release (ER) with SITA + MET sustained release (SR) and DAPA + MET ER in patients with type 2 diabetes poorly controlled with metformin. Methods:  This phase 3, randomized, open-label, active-controlled study included adult patients with glycated hemoglobin (HbA1c) ≥ 8% (64 mmol/mol) and ≤ 11% (97 mmol/mol), randomized in 1:1:1 ratio to receive either FDC of DAPA + SITA + MET ER (10 mg + 100 mg + 1000 mg) tablets once daily (n = 137) or co-administration of SITA + MET SR (100 mg + 1000 mg) tablets once daily (n = 139) or FDC of DAPA + MET ER (10 mg + 1000 mg) tablets once daily (n = 139). Primary endpoint was mean change in HbA1c from baseline to week 16. Results:  Mean baseline HbA1c was approximately 9% (75 mmol/mol) in each treatment group. At week 16, adjusted mean reduction in HbA1c from ba...
Read more

Monteflo 3D ( Montelukast + Fexofenadine + Acebrophylline ) from Edinburgh Pharmaceutical

-
Image
Montelukast + Fexofenadine + Acebrophylline is a combination of three medicines: Montelukast, Fexofenadine and Acebrophylline. Montelukast is a leukotriene antagonist. It works by blocking the action of leukotriene, a chemical messenger.  This reduces inflammation in the airways and nose, and improves symptoms of allergies. Fexofenadine is an antiallergic which relieves symptoms like runny nose, watery eyes and sneezing. Acebrophylline is a mucolytic which thins and loosens mucus (phlegm), making it easier to cough out. Courte sy  Dr. Sakshi Sharma , Dr. Ashish Ranjan Get More Information Click On This Website Link  -  www.edinburghpharma.in   and  QR Code Click on Social Accounts - Facebook , LinkedIn & YouTube  Keywords :   #Pharma Franchise in Odisha #Anti-Diabetic PCD# Best PCD Pharma Franchise Company# High Quality Pharma Product# Third Party manufacturing # Top 10 Pharma Franchise# PCD in Uttar Pradesh# Monopoly Phama PCD# Best...
Read more

Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia. The leading brand of Tamiflo D range being promoted by Edinburgh Pharmaceuticals in India.

-
Image
  Abstract Background We performed a meta-analysis to confirm the efficacy and safety of the combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia (BPH) during a treatment cycle of at least 1 year. Methods Randomized controlled trials were searched by using MEDLINE, EMBASE, and the Cochrane Controlled Trials Register. Systematic review was carried out using the Preferred Reporting Items for Systematic Reviews and Meta-analyses. The data was evaluated and statistically analyzed by using RevMan version 5.3.0. Results Five studies including 4348 patients were studied. The analysis found that the combination group was significantly greater effect in international prostate symptom score (mean difference [MD], − 1.43; 95% confidence interval [CI], − 2.20 to − 0.66;  P  = 0.0003), prostate volume (MD, − 10.13; 95% CI, − 12.38 to − 7.88;  P  < 0.00001), transitional zone volume (MD, − 3.18; 95% CI, − 3.57 to − ...
Read more